Baseline Mitochondrial DNA (mtDNA) Copy Number (CN) Among ALIVE Participants, by Participant Characteristics
| Characteristic . | Overall, No. (%) (n = 741) . | mtDNA CN, Mean ± SD . | Pa . |
|---|---|---|---|
| Age group, y | .82 | ||
| <50 | 439 (59.2) | −0.125 ± 1.02 | |
| ≥50 | 302 (40.8) | −0.107 ± 0.95 | |
| Sex | .09 | ||
| Male | 458 (61.8) | −0.154 ± 1.00 | |
| Female | 283 (38.2) | −0.061 ± 0.98 | |
| Race | .16 | ||
| Nonblack | 105 (14.0) | −0.233 ± 0.93 | |
| Black | 637 (86.0) | −0.099 ± 1.00 | |
| Education level | .94 | ||
| Less than high school | 317 (43.0) | −0.114 ± 0.92 | |
| High school or greater | 420 (57.0) | −0.121 ± 1.05 | |
| Current smoker | .32 | ||
| No | 125 (16.9) | −0.027 ± 0.89 | |
| Yes | 614 (83.1) | −0.133 ± 1.01 | |
| Current alcohol user | .01 | ||
| No | 375 (50.6) | −0.037 ± 0.96 | |
| Yes | 366 (49.4) | −0.201 ± 1.02 | |
| Current injection drug user | .04 | ||
| No | 436 (58.8) | −0.074 ± 0.93 | |
| Yes | 305 (41.2) | −0.181 ± 1.08 | |
| Anti-HCV status | .02 | ||
| Negative | 88 (11.9) | 0.107 ± 0.88 | |
| Positive | 653 (88.1) | −0.148 ± 0.99 | |
| Exposure to thymidine analogs | .21b | ||
| HIV negative persons | 305 (41.2) | −0.008 ± 0.957 | |
| HIV-positive persons never exposed | 241 (32.5) | −0.176 ± 1.038 | |
| HIV-positive persons ever exposed | 195 (26.3) | −0.218 ± 0.9979 |
| Characteristic . | Overall, No. (%) (n = 741) . | mtDNA CN, Mean ± SD . | Pa . |
|---|---|---|---|
| Age group, y | .82 | ||
| <50 | 439 (59.2) | −0.125 ± 1.02 | |
| ≥50 | 302 (40.8) | −0.107 ± 0.95 | |
| Sex | .09 | ||
| Male | 458 (61.8) | −0.154 ± 1.00 | |
| Female | 283 (38.2) | −0.061 ± 0.98 | |
| Race | .16 | ||
| Nonblack | 105 (14.0) | −0.233 ± 0.93 | |
| Black | 637 (86.0) | −0.099 ± 1.00 | |
| Education level | .94 | ||
| Less than high school | 317 (43.0) | −0.114 ± 0.92 | |
| High school or greater | 420 (57.0) | −0.121 ± 1.05 | |
| Current smoker | .32 | ||
| No | 125 (16.9) | −0.027 ± 0.89 | |
| Yes | 614 (83.1) | −0.133 ± 1.01 | |
| Current alcohol user | .01 | ||
| No | 375 (50.6) | −0.037 ± 0.96 | |
| Yes | 366 (49.4) | −0.201 ± 1.02 | |
| Current injection drug user | .04 | ||
| No | 436 (58.8) | −0.074 ± 0.93 | |
| Yes | 305 (41.2) | −0.181 ± 1.08 | |
| Anti-HCV status | .02 | ||
| Negative | 88 (11.9) | 0.107 ± 0.88 | |
| Positive | 653 (88.1) | −0.148 ± 0.99 | |
| Exposure to thymidine analogs | .21b | ||
| HIV negative persons | 305 (41.2) | −0.008 ± 0.957 | |
| HIV-positive persons never exposed | 241 (32.5) | −0.176 ± 1.038 | |
| HIV-positive persons ever exposed | 195 (26.3) | −0.218 ± 0.9979 |
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range.
aBy the Wilcoxon rank sum test, unless otherwise indicated.
bBy the Kruskal-Wallis equality-of-populations rank test.
Baseline Mitochondrial DNA (mtDNA) Copy Number (CN) Among ALIVE Participants, by Participant Characteristics
| Characteristic . | Overall, No. (%) (n = 741) . | mtDNA CN, Mean ± SD . | Pa . |
|---|---|---|---|
| Age group, y | .82 | ||
| <50 | 439 (59.2) | −0.125 ± 1.02 | |
| ≥50 | 302 (40.8) | −0.107 ± 0.95 | |
| Sex | .09 | ||
| Male | 458 (61.8) | −0.154 ± 1.00 | |
| Female | 283 (38.2) | −0.061 ± 0.98 | |
| Race | .16 | ||
| Nonblack | 105 (14.0) | −0.233 ± 0.93 | |
| Black | 637 (86.0) | −0.099 ± 1.00 | |
| Education level | .94 | ||
| Less than high school | 317 (43.0) | −0.114 ± 0.92 | |
| High school or greater | 420 (57.0) | −0.121 ± 1.05 | |
| Current smoker | .32 | ||
| No | 125 (16.9) | −0.027 ± 0.89 | |
| Yes | 614 (83.1) | −0.133 ± 1.01 | |
| Current alcohol user | .01 | ||
| No | 375 (50.6) | −0.037 ± 0.96 | |
| Yes | 366 (49.4) | −0.201 ± 1.02 | |
| Current injection drug user | .04 | ||
| No | 436 (58.8) | −0.074 ± 0.93 | |
| Yes | 305 (41.2) | −0.181 ± 1.08 | |
| Anti-HCV status | .02 | ||
| Negative | 88 (11.9) | 0.107 ± 0.88 | |
| Positive | 653 (88.1) | −0.148 ± 0.99 | |
| Exposure to thymidine analogs | .21b | ||
| HIV negative persons | 305 (41.2) | −0.008 ± 0.957 | |
| HIV-positive persons never exposed | 241 (32.5) | −0.176 ± 1.038 | |
| HIV-positive persons ever exposed | 195 (26.3) | −0.218 ± 0.9979 |
| Characteristic . | Overall, No. (%) (n = 741) . | mtDNA CN, Mean ± SD . | Pa . |
|---|---|---|---|
| Age group, y | .82 | ||
| <50 | 439 (59.2) | −0.125 ± 1.02 | |
| ≥50 | 302 (40.8) | −0.107 ± 0.95 | |
| Sex | .09 | ||
| Male | 458 (61.8) | −0.154 ± 1.00 | |
| Female | 283 (38.2) | −0.061 ± 0.98 | |
| Race | .16 | ||
| Nonblack | 105 (14.0) | −0.233 ± 0.93 | |
| Black | 637 (86.0) | −0.099 ± 1.00 | |
| Education level | .94 | ||
| Less than high school | 317 (43.0) | −0.114 ± 0.92 | |
| High school or greater | 420 (57.0) | −0.121 ± 1.05 | |
| Current smoker | .32 | ||
| No | 125 (16.9) | −0.027 ± 0.89 | |
| Yes | 614 (83.1) | −0.133 ± 1.01 | |
| Current alcohol user | .01 | ||
| No | 375 (50.6) | −0.037 ± 0.96 | |
| Yes | 366 (49.4) | −0.201 ± 1.02 | |
| Current injection drug user | .04 | ||
| No | 436 (58.8) | −0.074 ± 0.93 | |
| Yes | 305 (41.2) | −0.181 ± 1.08 | |
| Anti-HCV status | .02 | ||
| Negative | 88 (11.9) | 0.107 ± 0.88 | |
| Positive | 653 (88.1) | −0.148 ± 0.99 | |
| Exposure to thymidine analogs | .21b | ||
| HIV negative persons | 305 (41.2) | −0.008 ± 0.957 | |
| HIV-positive persons never exposed | 241 (32.5) | −0.176 ± 1.038 | |
| HIV-positive persons ever exposed | 195 (26.3) | −0.218 ± 0.9979 |
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range.
aBy the Wilcoxon rank sum test, unless otherwise indicated.
bBy the Kruskal-Wallis equality-of-populations rank test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
